Diazyme kits incorporate PNA (peptide nucleic acid) technology:
This article was originally published in Clinica
Executive Summary
The Diazyme Laboratories division of General Atomics (La Jolla, California) introduced SNP detection kits for Factor V Leiden and MTHFR C667T at the American Association of Clinical Chemistry meeting in Chicago, Illinois last week. The kits incorporate peptide nucleic acid (PNA) technology licensed from Boston Probes (Bedford, Massachusetts). Factor V Leiden is the most common inherited coagulation disorder in the US population, and increases the risk of venous thrombosis in homozygous individuals up to 140-fold. The MTHFR C667T mutation is linked with DVT, heart attack and stroke.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.